BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/10/2025 7:48:09 AM | Browse: 3 | Download: 3
 |
Received |
|
2025-08-27 23:10 |
|
Peer-Review Started |
|
2025-08-27 23:11 |
|
First Decision by Editorial Office Director |
|
2025-09-20 02:27 |
|
Return for Revision |
|
2025-09-20 02:27 |
|
Revised |
|
2025-10-02 20:34 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-11-04 02:33 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-11-04 08:39 |
|
Articles in Press |
|
2025-11-04 08:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-04 06:50 |
|
Publish the Manuscript Online |
|
2025-12-10 07:48 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Health Care Sciences & Services |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chu-Ying Sun and Ming-Xian Chen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming-Xian Chen, Chief Physician, MD, Professor, Department of Gastroenterology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Hangzhou 310012, Zhejiang Province, China. chenmingxian2005@126.com |
| Key Words |
Helicobacter pylori; Vonoprazan; Multicenter trial; Regional differences; Clinical implementation |
| Core Tip |
Han et al’s multicenter trial demonstrates vonoprazan triple therapy’s superior efficacy over standard bismuth quadruple therapy for Helicobacter pylori eradication in China, successful nationwide implementation faces critical challenges. Key barriers include limited drug accessibility in primary healthcare settings, higher costs compared to traditional therapies, and significant regional variations in antibiotic resistance patterns across China’s diverse population. The study’s single-province design cannot fully represent national applicability. Addressing these implementation gaps through comprehensive health system research, cost-effectiveness analyses, and multi-regional validation studies is essential for translating these promising clinical findings into improved patient outcomes across China’s heterogeneous healthcare landscape. |
| Publish Date |
2025-12-10 07:48 |
| Citation |
Sun CY, Chen MX. Additional considerations on vonoprazan triple therapy for Helicobacter pylori eradication: Implementation challenges and clinical perspectives. World J Gastroenterol 2025; 31(46): 113528 |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i46/113528.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i46.113528 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
